InvestorsObserver
×
News Home

What is the Market's View on Seagen Inc (SGEN) Stock's Price and Volume Trends Tuesday?

Tuesday, September 07, 2021 12:57 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Seagen Inc (SGEN) Stock's Price and Volume Trends Tuesday?

The market has been down on Seagen Inc (SGEN) stock recently. SGEN gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Seagen Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SGEN!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SGEN Stock Today?

Seagen Inc (SGEN) stock is trading at $149.12 as of 12:55 PM on Tuesday, Sep 7, a loss of -$3.10, or -2.04% from the previous closing price of $152.22. The stock has traded between $148.49 and $151.38 so far today. Volume today is less active than usual. So far 333,541 shares have traded compared to average volume of 695,658 shares.

More About Seagen Inc

Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer and Tukysa for breast cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies. Click Here to get the full Stock Report for Seagen Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App